- Sputnik International, 1920
Russia
The latest news and stories from Russia. Stay tuned for updates and breaking news on defense, politics, economy and more.

Russia Officially Launches Production of Its Third COVID-19 Vaccine

© Chumakov research instituteIn this handout photo released by the Chumakov research institute, Russia's CoviVac coronavirus vaccine, the third vaccine against COVID-19 registered in Russia, is pictured in Moscow, Russia
In this handout photo released by the Chumakov research institute, Russia's CoviVac coronavirus vaccine, the third vaccine against COVID-19 registered in Russia, is pictured in Moscow, Russia - Sputnik International, 1920, 25.03.2021
Subscribe
MOSCOW (Sputnik) - Russia's Chumakov research centre officially launched production of the country's third coronavirus vaccine, CoviVac, the Ministry of Science and Higher Education said on Thursday.

Russian Minister of Science and Higher Education Valery Falkov launched the first package of vaccine ampoules, labelled 0001.

"This means, the third Russian vaccine enters civil circulation and will be available in the regions in the coming days", the ministry said in a statement.
© Sputnik / Vitaly Belousov / Go to the mediabankA healthcare worker prepares a dose of Russia's coronavirus vaccine Gam-COVID-Vac, trade-named Sputnik V, at a coronavirus vaccination center at a shopping mall, in Moscow, Russia.
Russia Officially Launches Production of Its Third COVID-19 Vaccine - Sputnik International, 1920, 25.03.2021
A healthcare worker prepares a dose of Russia's coronavirus vaccine Gam-COVID-Vac, trade-named Sputnik V, at a coronavirus vaccination center at a shopping mall, in Moscow, Russia.

Apart from the new vaccine, Russia also plans to produce over 88 million doses of anti-coronavirus medications by June 2021, including 83 million doses of Sputnik V and 5.4 million doses of EpiVacCorona.

CoviVac, registered in February, became the third vaccine developed in Russia, after Sputnik V and EpiVacCorona. According to the authorities, the vaccine is currently recommended for people aged between 18 and 60, with an expansion possible following phase 2 trials.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала